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Abstract
Glucose metabolism is essential for the brain: it not only provides the required energy for cellular function and communication
but also participates in balancing the levels of oxidative stress in neurons. Defects in glucose metabolism have been described in
neurodegenerative disease; however, it remains unclear how this fundamental process contributes to neuronal cell death in these
disorders. Here, we investigated the molecular mechanisms driving the selective neurodegeneration in an ataxic mouse model
lacking oxidation resistance 1 (Oxr1) and discovered an unexpected function for this protein as a regulator of the glycolytic
enzyme, glucose-6-phosphate isomerase (GPI/Gpi1). Initially, we present a dysregulation of metabolites of glucose metabolism
at the pre-symptomatic stage in the Oxr1 knockout cerebellum. We then demonstrate that Oxr1 and Gpi1 physically and
functionally interact and that the level of Gpi1 oligomerisation is disrupted when Oxr1 is deleted in vivo. Furthermore, we show
that Oxr1 modulates the additional and less well-understood roles of Gpi1 as a cytokine and neuroprotective factor. Overall, our
data identify a newmolecular function for Oxr1, establishing this protein as important player in neuronal survival, regulating both
oxidative stress and glucose metabolism in the brain.
Keywords Oxidative stress . Glucose metabolism . Neurodegeneration . Cerebellum .Mouse
Introduction
The human brain consumes 20% of the total energy utilised by
the body at rest while accounting for only 2% of the total mass
[1]. To meet this particularly high energy demand, the brain
uses glucose as the predominant energy substrate under phys-
iological conditions [2]. Glucose is processed by oxidative
catabolism (glycolysis and the pentose phosphate pathway
(PPP)) in addition to oxidative phosphorylation (tricarboxylic
acid (TCA) cycle) in mitochondria. In contrast to other cell
types, some subtypes of neurons preferentiallymetabolise glu-
cose via the PPP to reduce the level of potentially damaging
reactive oxygen species (ROS) that are produced by oxidative
phosphorylation [2].
It has long been recognised that the brain is particularly
vulnerable to changes in glucose metabolism, and this appar-
ent sensitivity may be an important feature in neurological
disease. For example, imaging studies of patients at the early
symptomatic stages of amyotrophic lateral sclerosis (ALS)
demonstrate hypermetabolism (an increase in glucose use) in
the central nervous system (CNS), which correlates with dis-
ease progression [3, 4]. Conversely, hypometabolism is ob-
served in the striatum of patients affected by Huntington’s
disease (HD) [5] or in specific brain areas affected in patients
with Alzheimer’s disease (AD) [6]. Furthermore, in addition
to glucose usage, the expression of metabolic enzymes has
been shown to be disrupted in neurodegenerative conditions;
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reduced expression of α-glucosidase—the enzyme that de-
grades glycogen to glucose—is observed in laser-captured
motor neurons from post-mortem ALS spinal cords [7], and
glucose-6-phosphate isomerase (Gpi1) (also termed GPI in
human, phosphoglucose isomerase (PGI), neuroleukin
(NLK), or autocrine motility factor (AMF)) is upregulated in
the brain of a mouse model of HD [8]. Similarly, the activity of
glycolytic enzymes is often deregulated in neurodegenerative
diseases; for instance, the activities of pyruvate kinase and
lactate dehydrogenase are increased in brain areas affected in
AD, while the activities of phosphofructokinase and phospho-
glycerate mutase are decreased in the same anatomical regions
[9, 10]. Taken together, these studies suggest that the deregu-
lation of glucose metabolism may be an important feature of
the neurodegenerative disease process.
Oxidative stress is also a well-established contributing fac-
tor in neurodegeneration, with evidence that damage caused
by excess ROS is a key aspect of the region-specific pathology
observed in disease (reviewed in [11]). Crucially, glucose me-
tabolism and oxidative stress are two pathways that are func-
tionally intertwined; ROS inhibits glycolytic enzymes, lead-
ing to activation of the oxidative arm of the PPP to generate
NADPH that provides the reducing power of the antioxidant
system (reviewed in [11]). Thus, proteins that function at the
intersection of these two critical pathwaysmay provide a route
to modulating neuronal metabolism as a novel therapeutic
strategy in neurodegeneration.
The oxidation resistance 1 (Oxr1) gene was first identified
in a human cDNA library screen for genes that could rescue
the DNA oxidation repair-defective phenotype of a spontane-
ous Escherichia coli mutant [12]. It has since been defined as
an important oxidative stress-associated neuroprotective fac-
tor (reviewed in [13]). We have described previously that mice
lacking Oxr1 display degeneration of cerebellar granule cells
(CGCs) correlating with a progressive and rapid deterioration
of motor coordination and a shortened lifespan [14]. In addi-
tion, it has been established that the expression level of Oxr1
confers sensitivity to oxidative stress-associated insults; neu-
rons over-expressing Oxr1 are protected, while Oxr1 knock-
down increases the vulnerability of neurons to degeneration
[14]. Significantly, enhanced Oxr1 levels are protective
against neuronal death in both cellular and mouse models
of ALS [15–17], and these protective properties appear to
rely on a fully-functional TLDc domain, a highly evolu-
tionary conserved C-terminal motif in OXR1 [13, 16, 18].
This particular domain is found in a family of proteins that
includes nuclear receptor coactivator 7 (NCOA7) [16, 18]
and TBC1 domain family member 24 (TBC1D24) [16, 19].
In particular, TBC1D24 is mutated in a range of neurolog-
ical disorders characterised by seizures, neurodegenera-
tion, and hearing loss [20, 21]. Yet, despite the obvious
significance of the TLDc family in the CNS, the molecular
function of these proteins remains unclear.
Here, we investigated the molecular mechanisms of Oxr1
function in the CNS, and the pre-symptomatic pathways that
drive the selective cerebellar neurodegeneration observed in
mice lacking Oxr1. Using a combination of metabolomic and
biochemical approaches, we demonstrate an unexpected role
for Oxr1 as a regulator of the glycolytic enzyme, Gpi1. We
also show that Oxr1 is a direct protein interactor of Gpi1.
Furthermore, Oxr1 appears to modulate key functional aspects
of Gpi1, including the formation of multimeric species and the
role of the protein as a cytokine. Together, these data suggest
that the disruption of normal Gpi1 function and of the glyco-
lytic response in the cerebellum contributes to the selective
neurodegeneration in Oxr1 knockout mice.
Results
Loss of Oxr1 Disrupts Normal Glycolytic Metabolism
in the Cerebellum
We have described previously an Oxr1 mouse model in
which the TLDc domain—present in all Oxr1 isoforms—
is disrupted by insertion of a lacZ reporter [16]. Based on
the same mouse line, we generated mice with constitutive
deletion of two exons of the TLDc domain leading to trun-
cation of the protein (Fig. 1a and Supplementary Fig. 1). In
Fig. 1 Glucose metabolism is deregulated in Oxr1 knockout mice. a
Schematic indicating the exon structure of the longest full-length (FL)
and shortest C-terminal (C) Oxr1 isoforms with the relative position of
qRT-PCR primers indicated (arrows). The Oxr1 tm1d knockout allele is
also shown that truncates all Oxr1 protein isoforms. Coding exons
(white), UTRs (grey), an alternatively-spliced exon (yellow), and the
TLDc domain (blue) are shown. Not to scale. b qRT-PCR of 5′ exons
of Oxr1-FL and the Oxr1-C isoform in the cerebellum of Oxr1d/d mice
(N = 4 animals per group). cWestern blot of Oxr1-FL protein in cerebel-
lum tissue of homozygous Oxr1d/d mice compared to a wild-type control
(Oxr1+/+); alpha-tubulin was used as a loading control. d Representative
TUNEL staining of cerebellum sections from Oxr1d/d and littermate con-
trol mice at P18 compared to disease end-stage at P24 with quantification
of TUNEL-positive cells at P24 (N = 3 animals per group). Scale bar:
200 μm. e PCA analysis of metabolite profiling; each point on the PCA
plot represents an individual sample. PCA analysis of metabolite profiles
from cerebella of P18 Oxr1d/d (blue) compared to Oxr1+/+mice (green)
(N = 5 animals per group). f Twenty-three metabolites significantly dys-
regulated by more than 1.6-fold in the cerebella of P18Oxr1d/d compared
to Oxr1+/+ mice. Fold-changes are based on per-run abundances for a
specific metabolite which were then grouped by experimental condition
(N = 4-5 animals per group). g Metabolites dysregulated in the Oxr1d/d
cerebellum that are featured in pathways downstream of glucose-6-
phosphate isomerase. The fold-changes between Oxr1+/+ and Oxr1d/d
mice of the indicated metabolites are colour-coded. The position of the
glycolytic enzyme glucose-6-phosphate isomerase (Gpi1) in the pathway
is shown. A more detailed representation of the data is shown in
Supplementary Fig. 2. h Fructose-6-phosphate levels are increased in
the cerebellum but not the remaining brain tissue of Oxr1d/d mice com-
pared to littermate Oxr1+/+ controls (N = 4 animals per group). Panels b,
d, and h: t test, panel f, one-way ANOVA: *p < 0.05, **p < 0.01, ***p <
0.001
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mice homozygous for this mutant Oxr1tm1d allele (hence-
forth Oxr1d/d), the shortest isoform (Oxr1-C) was not
expressed in the brain, while the N-terminal end of the full
length isoform (Oxr1-FL) was still transcribed (Fig. 1b).
Importantly, however, the Oxr1-FL isoform was not detect-
able at the protein level in Oxr1d/d mutants compared to
wild-type littermate controls (Oxr1+/+) (Fig. 1c). Oxr1d/d
mice appear initially to be phenotypically normal until
post-natal day (P)19 when they begin to display an ataxic
phenotype and selective CGC degeneration (Fig. 1d); this
is an identical time-course of cerebellar-specific neurode-
generation as the two previously described mouse models
lacking Oxr1: the lacZ insertional mutant [16] and the orig-
inal mutant (bella) we described in which the entire Oxr1
locus was deleted [14].
Regulation of energy metabolism in the cerebellum is crit-
ical for granule cells, which have been predicted to consume
most of the glucose in this brain region to generate resting and
action potentials and maintain post-synaptic receptors [22].
Thus, given that granule cells are specifically affected in
Oxr1d/d mice, we hypothesised that dysregulation of glucose
metabolism may drive the neurodegeneration and ataxia ob-
served. To investigate this, metabolic profiling was performed
using anion-exchange tandem mass spectrometry from cere-
bella of pre-symptomatic P18Oxr1d/d and wild-type littermate
controls [23–25].
Authentic standards were used to identify metabolites as-
sociated with central metabolism including glycolysis, PPP,
and the TCA cycle. We used principal component analysis
(PCA) to model identified and unidentified compounds and
their abundances. Compound abundances across all samples
in the dataset were plotted in multi-dimensional space as rep-
resented on the PCA plot, where the first two principle com-
ponents of the PCA represent the projections that best discrim-
inate the samples (Fig. 1e). It can be seen that this discrimina-
tion divides Oxr1+/+ and Oxr1d/d extracts, suggesting that
there are significant differences in metabolite composition be-
tween these two groups. No sample outliers were shown in
this dataset, and the principle components 1 and 2 account for
34 and 15% of the total variance in the dataset, respectively.
Therefore, these analyses suggested that, in the cerebellum,
the two genotypes possessed distinct pre-symptomatic metab-
olite profiles. Using this approach in combination with calcu-
lated fold-changes in abundance, we identified 111 metabo-
lites; of the 52 metabolites significantly deregulated (p value
< 0.05), 45 were elevated in the Oxr1d/d samples compared to
wild-type, while 7 were depleted (Fig. 1f and Supplementary
Table 1). Interestingly, glycolytic metabolites showed gener-
ally elevated levels in the Oxr1d/d cerebellum samples com-
pared to Oxr1+/+; these included those in the first catalytic
steps of glycolysis as well as pyruvate, the last metabolite in
the process (Fig. 1g and Supplementary Fig. 2).
Given that the initial steps of glycolysis—and in particular
glucose-6-phosphate and fructose-1,6-bisphosphate—were
significantly enriched, we decided to help validate these ob-
servations using an alternative biochemical assay on an inde-
pendent set of tissues. Thus, we chose to quantify the levels of
fructose-6-phosphate, the first metabolic product in glycolysis
formed from glucose-6-phosphate, as the metabolomics anal-
ysis was not able to quantify this metabolite reliably.
Consistent with the deregulation of glycolysis observed by
metabolic profiling, we showed a significant increase of 2.9-
fold in the cerebellum of Oxr1d/d mice compared to their lit-
termate controls at P18 (Fig. 1h). Interestingly, a non-
significant increase was detectable in the remaining brain tis-
sue of the same animals (Fig. 1h), suggesting a specific and
more pronounced dysregulation of this metabolite in the cer-
ebellum at a pre-symptomatic stage of Oxr1d/d mice, in-line
with the selective neurodegeneration observed. In summary,
both metabolic profiling by mass spectrometry and a bio-
chemical assay from the Oxr1d/d cerebellum showed a clear
imbalance in the levels of energetic metabolites prior to symp-
tom onset, especially those in the glycolytic pathway and PPP
(Supplementary Fig. 2).
Oxr1 Interacts with Glucose-6-Phosphate Isomerase
We reasoned that because multiple parallel pathways associ-
ated with glucose-6-phosphate were affected in the Oxr1d/d
cerebellum (Fig. 1g), Oxr1 might act on a protein that
metabolises glucose-6-phosphate, such as glucose-6-
phosphate isomerase (GPI in human/Gpi1 in mouse). GPI is
not only a key enzyme at the crossroads of the glycolytic, PPP,
and glucuronic acid pathways [26], it can also act as a chemo-
kine that stimulates cell proliferation and migration [27–29].
Moreover, mutations in GPI have been identified in patients
with neuromuscular dysfunction and mental retardation
[30–34]. Thus, given the potential role played by GPI in the
CNS, we first tested whether Oxr1 and Gpi1 proteins could
physically interact. In a cell line co-expressing either the full-
length (Oxr1-FL) or the shortest TLDc domain-containing
(Oxr1-C) isoforms with Gpi1, a direct interaction could be
observed with both isoforms by co-immunoprecipitation
(Fig. 2a). These data suggest not only that both Oxr1 isoforms
bind to Gpi1 but also that the TLDc domain is critical for this
interaction. Unfortunately, we were unable to reproducibly
Fig. 2 Oxr1 interacts with the glycolytic enzyme, glucose-6-phosphate
isomerase. a Co-immunoprecipitation in HeLa cells over-expressing
MYC-tagged Gpi1 with HA-tagged Oxr1-FL or Oxr1-C. b Gpi1 activity
from whole cerebellum or remaining brain tissue of Oxr1d/d mice com-
pared to Oxr1+/+ controls (N = 4–8 animals per group). c Gpi1 activity in
N2a cells transfected with an shRNA against either Oxr1 or Gpi1 or
corresponding control vector (shRNA scramble) (N = 4 independent re-
peats). Panel b: t test, panel c: one-way ANOVA; **p < 0.01
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immunoprecipitate Gpi1 with Oxr1 in vivo due to a lack of
reliable antibodies. Therefore, we investigated next whether
loss of Oxr1 in vivo would affect the enzymatic activity of
Gpi1. In cerebellar tissue, Gpi1 activity was increased but not
significantly altered in Oxr1d/d mice compared to control lit-
termates, and no change was detected in the remainder of the
brain from the same animals (Fig. 2b). To focus on the role of
Oxr1 and Gpi1 in neurons without the potential confound of
other cell types, we next tested whether Oxr1 levels would
affect Gpi1 activity in a neuronal cell line, Neuro2a (N2a).
To mimic the Oxr1 knockout condition, we transfected N2a
cells with a shRNA construct against Oxr1 to significantly
reduce Oxr1 levels (Supplementary Fig. 3). Similar to what
we observed in vivo, reduction of Oxr1 expression levels did
not significantly affect Gpi1 activity (Fig. 2c).
Loss of Oxr1 Influences Glycolytic Function
Under Oxidative Stress
Next, we tested systematically which of the multiple aspects
of Gpi1 function might be affected by Oxr1 in the brain. Gpi1
is a key glycolytic enzyme responsible for the non-committal
interconversion between glucose-6-phosphate and fructose-6-
phosphate [26]. To gain insight into whether loss of Oxr1 had
any direct consequences for the glycolytic function of cells in
the granule cell layer of the cerebellum, we determined the
capacity of primary CGCs from Oxr1d/d and wild-type con-
trols to carry-out glycolysis when ATP production is inhibited.
We measured glycolysis in real-time via the quantification of
the extracellular acidification rate (ECAR) of the media in
glucose-starved CGCs [35]. First, glucose was injected into
the medium, followed by oligomycin to inhibit mitochondrial
ATP synthase, and finally 2-deoxy-D-glucose (2-DG) to in-
hibit glycolysis; this allows glycolysis, glycolytic capacity,
glycolytic reserve, and non-glycolytic acidification to be cal-
culated [36]. A similar ECAR profile was observed in untreat-
ed CGCs from Oxr1d/d mice compared to littermate controls
(Fig. 3a–b), although glycolytic capacity was significantly
increased in cells from mutant animals in response to mito-
chondrial inhibition (Fig. 3c). As Oxr1 plays a well-
established role in protecting against oxidative stress-
associated cell death, we next tested the ability of primary
CGCs from Oxr1d/d mice to regulate their glycolytic function
under oxidative stress conditions. After pre-treatment with
arsenite to induce oxidative stress, wild-type CGCs signifi-
cantly reduced their glycolytic capacity as compared to un-
treated wild-type cells (Fig. 3d), while the other parameters
were not significantly affected; this observation may represent
an adaptive glycolytic response to prevent further production
of ROS [11]. In contrast, when we compared the profile of
cells from Oxr1d/d mice in non-treated and in arsenite-treated
conditions, no significant change in ECAR was observed
(Fig. 3d). These data suggest that Oxr1d/d cells, unlike control
cells, do not adapt their glycolytic function when under oxi-
dative stress. Furthermore, after arsenite treatment, both gly-
colysis and glycolytic capacity were significantly higher in
CGCs from mutants compared to wild-type controls
(Fig. 3e–f). In summary, these data provide further evidence
that loss of Oxr1 leads to a significant disturbance of glyco-
lytic metabolism that becomes more pronounced under con-
ditions of oxidative stress.
Gpi1 Modulates the Neuroprotective Properties
of Oxr1
Both Gpi1 and Oxr1 have been shown to possess neuropro-
tective properties [14, 37–39], thus we investigated next
whether there was any correlation between the expression
levels of Gpi1 and Oxr1 and their neuroprotective function.
In a neuronal cell line treated with arsenite, cell death was
quantified when Gpi1 or either isoform of Oxr1 was over-
expressed. As previously described [16], both Oxr1-FL and
Oxr1-C significantly reduced neuronal cell death induced by
oxidative stress (Fig. 4a, Supplementary Fig. 3). Similarly,
over-expression of Gpi1 led to a significant reduction in cell
death (Fig. 4a); these data demonstrate that Gpi1, like Oxr1,
can protect neurons under these conditions. Conversely, using
shRNAs we confirmed that the reduction of Oxr1 expression
led to a significant increase in neuronal cell death compared to
a control scrambled shRNAvector in the same assay (Fig. 4b).
Knockdown of Gpi1 also led to a significant increase in cell
death compared to control cells, but to a lesser extent than
Oxr1 knockdown (Fig. 4b, Supplementary Fig. 3).
Importantly, when Oxr1 knockdown was combined with
over-expression of Gpi1, there was no increase in cell death
compared to cells transfected with control vectors (Fig. 4c,
Supplementary Fig. 3). Furthermore, no change in cell death
was observed when over-expression of either of the Oxr1
isoforms was combined with Gpi1 knockdown (Fig. 4c).
Given that cell death induced by loss of either Gpi1 or Oxr1
can only be partially rescued by the over-expression of the
other, this suggests that Gpi1 and Oxr1 are both important
for neuroprotection against oxidative stress and that they rely
on optimal expression levels of one another; thus providing
further evidence for a functional interaction between the two
proteins.
Loss of Oxr1 Influences the Cytokine Function of Gpi1
in Neuronal Cells
In addition to its glycolytic function and as a growth factor
promoting the survival of neurons, GPI can also act as a cy-
tokine to stimulate cell proliferation and migration [27–29,
40]. First, we determined whether Gpi1 could induce migra-
tion of neuronal cells, as this has only been investigated in
non-neuronal cells to date [41–43]. We quantified the
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migration of purified primary CGCs from wild-type mice
treated for 24-h with a range of recombinant Gpi1 concentra-
tions. We observed an increase in cell migration with increas-
ing Gpi1 concentrations, confirming that Gpi1 can promote
the migration of neuronal cells (Fig. 4d). Next, we went on to
examine whether levels of Oxr1 would affect this specific
aspect of Gpi1 function. We quantified the migration of cells
from primary CGCs from Oxr1d/d and littermate control mice
Fig. 3 Glycolysis is altered in granule cells of Oxr1 knockout mice. a The
extracellular acidification rate (ECAR) using the Seahorse glycolysis
stress test assay; the timing of the compounds added to the assay medium
are indicated (glucose to feed glycolysis, followed by oligomycin to in-
hibit mitochondrial ATP synthase and 2-deoxy-D-glucose (2-DG) to in-
hibit glycolysis) and the various parameters that can be calculated are
represented by arrows (non-glycolytic acidification (i), glycolysis (ii),
glycolytic capacity (iii), and glycolytic reserve (iv)). b–f ECAR assay
data from primary CGCs from Oxr1d/d and Oxr1+/+ mice in untreated
(b–d) or arsenite-treated (d–f) conditions (N = 4 animals per group for all
panels). For comparative purposes, panel d represents the data from
panels c and f. Panels b, e: two-way ANOVA, panels c, d, f: t test; *p
< 0.05, **p < 0.01
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after 24-h of treatment with the dose of recombinant Gpi1
protein determined previously (Fig. 4d–e). Interestingly, cells
from Oxr1d/d mice displayed a significantly reduced tendency
to migrate after Gpi1 exposure compared to wild-type cultures
(Fig. 4e–f). To control that the type and the properties of cells
migrating in this assay were not affected by treatment with
Gpi1, we confirmed that there was no significant difference
in the proportion of neuronal NeuN-positive (approximately
35%) and proliferating Ki67-positive cells (approximately
19%) in the CGC cultures used and treated with either vehicle
or Gpi1 (Fig. 4g–h). The extracellular receptor for Gpi1 is
glycoprotein 78 (Gp78), which is highly expressed in neurons
of the rodent brain [44, 45]. To confirm whether the reduced
migration of Oxr1d/d cells was not due to aberrant expression
of Gp78, we quantified RNA levels of this gene in cultures
used for themigration assay (Fig. 4i) as well as from cerebellar
and the non-cerebellar brain tissue from Oxr1d/d and control
wild-type mice (Fig. 4j). No significant differences in Gp78
expression were detected between the samples, suggesting
that cells require Oxr1 to respond normally to secreted Gpi1.
Thus, taken together, our data demonstrate an interaction be-
tween Gpi1 and Oxr1, which affects both neuroprotective
function of Gpi1 and the cellular response to Gpi1 as a
cytokine.
Oxr1 Influences the Oligomerisation of Gpi1
GPI can be present as a monomer or as multimers in the cell,
and the degree of oligomerisation is a key influence on its
function; the dimeric form is composed of a large and a small
domain, with the sugar binding site at the junction between
these two domains responsible for its enzymatic activity
[46–53]. The monomeric form of GPI, however, is considered
to be involved primarily as a cytokine without enzymatic ac-
tivity [28, 39, 52, 54, 55]. A tetrameric form of GPI has also
been observed in vitro and in vivo, although the function
of this species remains unknown [48, 54]. As we had
already demonstrated that Gpi1 and Oxr1 can bind to
one another, we next investigated whether this interaction
would influence the oligomerisation of Gpi1. Initially, we
co-transfected Gpi1 with either a control vector or Oxr1
in cells treated with the crosslinker and complex-
stabilising dithiobis(succinimidylpropionate) (DSP) [54]. Cells
over-expressing Gpi1 and treated with DSP presented three
forms of Gpi1: monomeric, dimeric, and tetrameric (Fig. 5a);
these dimeric and tetrameric forms were lost when protein ex-
tracts were incubated with β-mercaptoethanol and boiled to
break any intra- or inter-molecular disulfide interactions
(Fig. 5a) [54]. Interestingly, when co-transfected with Oxr1-FL,
the ratio of dimeric and tetrameric forms over monomeric Gpi1
form was significantly reduced, while the levels of monomeric
forms remained unchanged (Fig. 5). Such an effect was not ob-
served when co-transfected with Oxr1-C (Fig. 5b–c). This sug-
gests that Oxr1-FL can modulate Gpi1 oligomerisation in vitro.
Next, to investigate whether Oxr1 could modulate the level
of Gpi1 oligomerisation in vivo, we extracted proteins from
mouse cerebellar tissue in buffer conditions to preserve
protein-protein interactions (PPIs). Interestingly, there was a
significant increase in the absolute levels of Gpi1 tetramers
and dimers in Oxr1d/d cerebellum at the pre-symptomatic P18
timepoint compared to Oxr1+/+ controls as quantified by
western blotting (Fig. 5d–e). To test whether the apparent
changes in the proportion of the Gpi1 species were as a result
of alterations at the transcriptional level, we also quantified
Gpi1 RNA. From the cerebella of mice from both genotypes,
no significant difference in Gpi1 expression was observed
(Fig. 5f). Next, given that Oxr1 changes the proportion of
Gpi1 dimerization—which is essential for Gpi1 glycolytic ac-
tivity—we wanted to test whether an increase in Oxr1 may
affect Gpi1 activity in vitro. Cells over-expressing either Gpi1
or Oxr1-C showed a slight increase in Gpi1 activity as com-
pared to cells transfected with a control empty vector
(Fig. 5g). However, when co-transfected with Gpi1, Oxr1-
FL reduced Gpi1 activity approximately two-fold as com-
pared to cells co-expressing Gpi1 with an empty vector or
Oxr1-C (Fig. 5h). These data suggest that Oxr1-FL has a pro-
pensity to modulate Gpi1 dimerisation levels and is also able
to affect Gpi1 activity.
Disease-Causing Mutations in Gpi1 Influence Oxr1
Binding
GPI deficiency caused by genetic mutations is a known cause
of hemolytic anaemia [56–72]; a subset of these mutations is
also associated with neurological symptoms, including
Fig. 4 Gpi1 functions are modulated by Oxr1. a Over-expression of
Gpi1, Oxr1-FL, and Oxr1-C in N2a cells treated with arsenite and quan-
tification of pyknotic nuclei as a measure of cell death (N = 3 independent
repeats). b Knockdown of Oxr1 and Gpi1 by shRNA in arsenite-treated
N2a cells with quantification of pyknotic nuclei (N = 5 independent re-
peats). c Knockdown of Oxr1 and Gpi1 by shRNA together with either
Gpi1 or Oxr1 over-expression, respectively, with quantification of the
number of pyknotic nuclei (N > 5 independent repeats). d Wild-type
CGCs cultured on Transwell inserts were treated with increasing concen-
trations of recombinant of Gpi1 and the number of cells having migrated
through the insert were quantified (N = 2 repeats). e Representative im-
ages of CGCmigration after 24-h treatment with recombinant Gpi1. Scale
bar: 200 μm. f Quantification of migration coefficient in Oxr1d/d and
Oxr1+/+ cultures (N > 3 animals per group). g–h Relative composition
of primary cultures treated with either vehicle or recombinant Gpi1 and
quantified by immunocytochemistry using a neuronal marker (NeuN) and
a marker for proliferating cells (Ki67). Scale bar: 100 μm. i Expression of
Gpi1 and its receptor, Gp78, in CGCs from Oxr1d/d mice compared to
Oxr1+/+ by qRT-PCR (N = 4 animals per group). jGp78 RNA expression
levels in whole brain or cerebellum from P18 Oxr1d/d mice compared to
control littermates by qRT-PCR (N = 4–5 animals per group). Panels a–d:
one-way ANOVA; f, h–j: t test; *p < 0.05, **p < 0.01, ***p < 0.001 as
compared to shRNA scramble plus empty vector, shRNA scramble, emp-
ty vector, Oxr1+/+ or vehicle; ###p < 0.001 as compared to shRNA Oxr1
plus empty vector
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intellectual disability and neuromuscular dysfunction [30–34].
The reason for this disease spectrum remains unclear; howev-
er, predictions based on the three-dimensional structure of GPI
suggest that certain mutations may be more likely to affect
either the glycolytic or cytokine activities of the protein [51].
Thus, we investigated next whether the functional interaction
between Oxr1 and Gpi1 we discovered would be influenced
by conserved pathogenic GPI mutations.We chose to test a set
of mutations spanning the coding sequence that have been
associated specifically with either non-neurological (Q343R)
[60] or neurological (R104Q, L297F, L339P) symptoms [30,
33]. Using co-immunoprecipitation in cells expressing either
wild-type or mutant Gpi1 with Oxr1-FL, we showed that these
four particular mutations do not appear to affect the affinity
between the two proteins or their expression levels (Fig. 6a–
b). As we have demonstrated that Oxr1-C also binds to Gpi1,
the same set of co-immunoprecipitations was also carried out
with this short isoform (Fig. 6c–d). Interestingly, the L339P
Gpi1 mutation showed a significant increase in affinity for
Oxr1-C compared to wild-type Gpi1, although the level of
expression was not altered (Fig. 6d).
To gain a better understanding of the binding between Oxr1
and Gpi1, we used in silico modelling of the PPI between
these two proteins. In the absence of an atomically-detailed
structure of Oxr1, we produced a model of the TLDc domain
of mouse Oxr1 using the 0.97-Å resolution crystal structure of
the zebrafish TLDc domain fromOxr2 as a template [73]. The
resulting model was then used in combination with the struc-
ture of mouse Gpi1 as input to the protein-protein docking
ClusPro server to generate multiple docking models. As the
Oxr1-C isoform does not seem to significantly affect the
dimerisation levels of Gpi1 (Fig. 5), we studied the PPI of
the Oxr1 TLDc domain with Gpi1 in its monomeric, dimeric,
or tetrameric form (Fig. 6e–f). An exhaustive rigid-body pro-
tein docking was performed to identify the most favourable
interaction interface between the available TLDc domain
structure and Gpi1. Accordingly, the most populated cluster
showed that the TLDc domain overlaps the second Gpi1 pro-
tein of the Gpi1 dimer (Fig. 6e), suggesting that both proteins
share a common protein-protein interface.
Interestingly, the most populated cluster with the largest
number of low-energy conformations—and therefore the most
energetically favourable model—shows the TLDc domain
binding site overlapping the key neurodegenerative dis-
ease mutation residues R104 and L297 (Fig. 6g); this interac-
tion also involves several charged residues in the TLDc do-
main, including R126, D156, and E190. Of note, all three of
these amino acids are conserved in the TLDc domain of hu-
man and mouse NCOA7, the protein most closely related to
Oxr1, and two are conserved in human and mouse TBC1D24
[12, 16, 18]. Therefore, we tested the binding of mouse Ncoa7
and Tbc1d24 to Gpi1 and found that the interaction could be
detected reproducibly and specifically (Fig. 7). Together, these
findings provide further evidence that the TLDc domain is key
to the Gpi1 interaction; furthermore, as the loss of Oxr1 leads
to a global increase of oligomeric Gpi1 (Fig. 5), we could also
hypothesise that this predicted binding site is a new interface
that modulates transition of Gpi1 between monomeric and
multimeric forms.
Discussion
We have shown here that Oxr1 possess an unexpected func-
tion as a regulator of glucose metabolism, in particular under
oxidative stress conditions. This new role for Oxr1 is carried
out—at least in part—via a direct interaction with Gpi1. In
addition, we reveal that Oxr1 is the first protein described that
is able to modulate both the neuroprotective and cytokine
properties of the multi-functional Gpi1 protein.
Using theOxr1 knockout mouse model, we have identified
a new mechanistic link between glucose metabolism and neu-
rodegeneration in a defined region of the brain. It is also note-
worthy that the dysregulation of metabolite levels we ob-
served downstream of Gpi1 occurs at the pre-symptomatic
stage, suggesting that this metabolic disturbance plays a role
in the cerebellar-specific pattern of cell death. This apparent
selective vulnerability of the cerebellum has also begun to be
investigated in disorders, such as spinocerebellar ataxia (SCA)
using quantitative metabolite profiling. For example, in two
mouse models expressing a mutated SCA1 (Ataxin-1) gene
(82Q and 154Q/2Q), an increasing level of glutamine was
observed consistently in this region by magnetic resonance
spectroscopy (MRS) [74, 75]. Increased glutamine was also
detected in the cerebellum of SCA1 patients using the same
Fig. 5 Oxr1 modulates Gpi1 oligomerisation. a Dimerisation of Gpi1 in
cells co-transfected with Gpi1 and either an empty vector or full-length
(Oxr1-FL) or short (Oxr1-C) Oxr1 isoforms. Cells were treated with a
cross-linker (DSP) and proteins were extracted in PBS; the loading buffer
did not contain any reducing β-mercaptoethanol and samples were not
boiled (non-reducing conditions). As a control, protein extracts from cells
treated with DSP were incubated with the reducing agent β-
mercaptoethanol and boiled (DSPβ/b). Vinculin (Vin) levels were used
to control for equivalent loading. b–c Quantification of the dimeric (b) or
tetrameric (c) versus monomeric forms of Gpi1 (N = 6 independent re-
peats). d–e Western blot and quantification showing Gpi1 oligomeriza-
tion in cerebellum fromOxr1d/d andOxr1+/+mice from proteins extracted
in PBS and non-reducing conditions. Ponceau staining was used to con-
trol for equal loading. As a control, protein extracts from the same prep-
arations were incubated with the reducing agent β-mercaptoethanol and
boiled (β/b). α-Tubulin levels were used to control for equivalent loading
(N = 8 animals per group). f mRNA expression levels of Gpi1 in the
cerebellum of Oxr1+/+ or Oxr1d/d mice by qRT-PCR (N = 4 animals per
group). g Gpi1 activity in N2a cells transfected with the vectors indicated
compared to an empty vector control (N = 3–5 independent repeats). h
Gpi1 activity in N2a cells co-transfected with Gpi1 and either Oxr1-FL or
Oxr1-C (N = 3 independent repeats). Panels b, c, g, h: one-way
ANOVA; Panels e, f: t-test; *p < 0.05, **p < 0.01. Symbols #, ##, and
### represent Gpi1 monomer, dimer, and tetramer, respectively
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non-invasive method [76]. Importantly, there was no correla-
tion between glutamine levels and ataxia scores in
symptomatic patients or pathology scores in symptomatic
SCA1 mutant mice, suggesting that the accumulation of this
Fig. 6 Oxr1 binding affinity to Gpi1 is influenced by disease associated-
mutations. a–d Co-immunoprecipitations using an anti-MYC antibody
and direct protein extracts in cells co-expressing MYC-tagged Gpi1
(wild-type (WT) or mutant constructs) with HA-tagged Oxr1-FL (panels
a–b N = 3 independent repeats) or Oxr1-C (panels c–d N = 4 independent
repeats). e–f Predictions of the monomeric (e), dimeric (e), and tetrameric
(f) forms of mouse Gpi1 interacting with the TLDc domain. g
Representation of the Gpi1 dimer with the positions of the key residues
mutated and investigated highlighted. Panels b, d: one-way ANOVA; *p
< 0.05
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specific metabolite was a biochemical marker of the pre-
symptomatic disease state [74, 76]. More recently, proteomic
profiling of the cerebellum from homozygous Ataxin-1
knockout mice at a pre-symptomatic stage revealed expres-
sion changes in a range of key bioenergetic pathways, includ-
ing Gpi1 and other glycolytic enzymes [77]. Although the
molecular mechanisms linking mutant Ataxin-1 to these path-
ways are unknown, alongside our new data, these findings
suggest that metabolic disruption may be a key feature of
cerebellar disorders. Furthermore, levels of glucose and gly-
cogen—the main form of glucose storage in the brain—are
higher in the cerebellum than other brain regions, supporting
the hypothesis that the cerebellum is distinct from other brain
regions regarding its energy buffering capacity [78]. Whether
these data reflect the complex network connectivity require-
ments of the densely packed granule cell layer is still not
entirely clear [22]; in particular, as the importance of glucose
metabolism for non-neuronal—as well as neuronal—cell pop-
ulations in the CNS is only just beginning to be understood.
For example, astrocytes play an essential role in the uptake of
glucose, and the availability of metabolites can have a major
influence on astrocyte and glial cell function [79–81]. Given
that we have demonstrated previously that over-expression of
Oxr1 in vivo can delay the neuroinflammatory response in a
model of ALS [17], the relationship between glycolytic path-
ways and Oxr1 function in non-neuronal cells warrants further
investigation in the future.
Our in vivo data suggests that loss of Oxr1 increases Gpi1
affinity for its substrates and/or favours the reaction
converting glucose-6-phosphate to all three downstream met-
abolic pathways (glucuronic acid pathway, glycolysis, and
oxidative PPP). PPP in particular shows higher levels of
intermediates, particularly in the oxidative part of the pathway.
However, we did not detect a significant increase in Gpi1
activity in whole cerebella from Oxr1d/d mice. This could be
explained by the fact that Gpi1 activity is also inhibited by the
glycolytic or PPP intermediates, for example 6-phospho-
gluconic acid [82], which is significantly increased in cerebel-
la of Oxr1d/d mutants compared to controls in our study.
Our data in Oxr1 knockout brain tissue indicates that Oxr1
regulates the function of Gpi1 by modulating the ratio of mo-
nomeric to oligomeric forms and thus potentially favours
Gpi1 activity as a cytokine over its glycolytic role. Thus, to
understand the multiple aspects of Gpi1 functional regulation,
one needs to consider not only the expression of the protein
but also the degree of oligomerisation. Indeed, it has been
demonstrated using deletion mutants around a conserved cys-
teine motif that both the monomeric cytokine function and
ligand-receptor binding to Gp78 are independent of the enzy-
matic activity of GPI as a dimer [55]. Therefore, we used a
combination of molecular and in silico modelling approaches
to identify potential binding sites between Gpi1 and Oxr1 and
to study the effect of disease-associated mutations on binding
affinity. Clinically, GPI mutations significantly reduce the cat-
alytic activity of the protein; these measurements are made
typically from patients’ erythrocytes, although much of the
molecular data linking phenotype and genotype are based-
around the physiochemical properties of the GPI protein, such
as in vitro thermostability or electrophoretic mobility [30–32,
34, 59–65, 67, 69, 72, 83–85]. In addition, the molecular detail
of enzymatic dysfunction can be confounded by the presence
of compound heterozygous GPI mutations, where an un-
known complement of mutant catalytic dimers or heterodi-
mers will form in vivo [30, 33, 34, 60, 62, 63, 65–67, 70]. A
Fig. 7 Ncoa7 and Tbc1d24 are protein interactors of Gpi1. Co-immunoprecipitation in HeLa cells co-transfected with MYC-tagged Gpi1 and either a
control vector or HA-tagged Ncoa7, Tbc1d24, or an unrelated protein Prmt1 as a negative control.
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previous study examined mutants in the context of the GPI
three-dimensional data and classified them in distinct classes:
those that alter GPI structure and those that disrupt either its
oligomerization or active site [51]; thus it was hypothesised
that mutations influencing protein folding would affect both
the enzymatic and neurotrophic activities of GPI leading to
haemolytic and neurological symptoms in patients, while mu-
tations affecting the active site would disrupt the enzymatic
activity alone [30, 51, 70, 86]. Here, we demonstrated that
there were limited effects on binding affinity between Oxr1
and the selected pathogenic Gpi1 mutations, although the
shortest Oxr1-C isoform interacted with greater affinity to
the L339P mutant, a substitution that causes anaemia with
neuromuscular involvement when combined with a second
H20Pmutant GPI allele [30]. A study on recombinant proteins
has demonstrated that the L339P substitution significantly re-
duces the stability and catalytic activity of GPI, and it was
proposed that the new proline residue would disrupt multiple
internal hydrophobic bonds [85]. How Oxr1 functions in the
context of GPI deficiency is yet to be investigated, although it
is interesting that we have previously shown the utility of
Oxr1 over-expression in delaying neuromuscular-associated
phenotypes [17].
We showed previously that loss of Oxr1 led to an increase
in apoptotic cell death in the granule cell layer of the cerebel-
lum from P19 as well as in cultured primary CGCs under
oxidative stress [14]. Here, we investigated glycolysis under
oxidative stress conditions and discovered that CGCs lacking
Oxr1 do not reduce their glycolytic rate under oxidative stress,
as would be expected in wild-type cells to reduce the over-
production of ROS [11]. Thus, we can hypothesise that Oxr1
carries out its neuroprotective function, at least in part, by
modulating Gpi1 activity in order to inhibit the glycolytic
pathway and dampen ROS production. However, this func-
tional association is likely to be more complex; indeed, we
showed here that both the full-length and shortest TLDc
domain-containing isoforms of Oxr1 may influence Gpi1
function differently. These data are particularly interesting,
as Oxr1 isoforms have been reported to be differentially in-
duced under sustained oxidative stress conditions [15, 87, 88];
together these data suggest a model whereby Oxr1-FL en-
hances initially the ratio of monomeric to high molecular
weight species of Gpi1, while the glycolytic dimeric forms
are stabilised subsequently by Oxr1-C during oxidative stress.
Currently, however, it is unclear whether the binding of one
Oxr1 isoform to Gpi1 would prevent any interaction with
another Oxr1 isoform. In addition, we note that our modula-
tion of Gpi1 expression does not appear to impact cell death as
strongly as the knockdown or over-expression of Oxr1. These
data could suggest that—although Oxr1 binding to Gpi1 mod-
ulates glycolytic function and consequently ROS produc-
tion—this interaction influences another feature of Oxr1 that
plays a more direct role in cell survival; for example, by
impacting other PPIs [15]. Alternatively, these findings may
relate to the relative knockdown or over-expression efficien-
cies and mRNA levels obtained, or to unknown thresholds of
expression that are required to influence the particular path-
ways we have studied.
Our data also indicate that primary neurons lacking Oxr1
do not respond normally to stimulation by Gpi1 acting as an
extracellular chemokine. This particular function of GPI is
known to be signalled via an interaction with its extracellular
receptor (GP78). Therefore, in our particular assays, the func-
tional interaction between Oxr1 and Gpi1 may be indirect.
However, a study has demonstrated that extracellular mono-
meric GPI can be internalised by endocytosis [89], thus facil-
itating potential downstream interactions with proteins that
may influence cell migration. Further studies will be required
to examine this hypothesis.
Finally, in-line with the apparent importance of the TLDc
domain for this GPI interaction, we identified the related
TLDc proteins Ncoa7 and Tbc1d24 as additional novel bind-
ing partners for Gpi1, as predicted by conserved putative bind-
ing residues. This provides new molecular evidence that there
is functional overlap between TLDc proteins in the brain.
Moreover, these data may relate to specific pattern of cell
death in the Oxr1d/d cerebellum, a region where there is lim-
ited concordant expression of Oxr1 and Ncoa7 [16, 90]. In
other brain areas where no cell death occurs, such as the cere-
bral cortex and hippocampus, all three genes are highly co-
expressed, suggesting that Ncoa7 and Tbc1d24 may be able to
compensate functionally for loss of Oxr1 [16, 90].
The disruption of energy homeostasis is becoming a more
common theme in neurological disease with the discovery that
abnormal metabolic function occurs both prior to, and as part
of, the pathological process. Here, we have shown that glyco-
lytic imbalance is a feature of cerebellar neurodegeneration in
Oxr1 knockout mice, and that multiple aspects of Gpi1 func-
tion can be modulated by the Oxr1 protein itself. There is still
much to learn regarding the role of GPI in the nervous system;
indeed, it is noteworthy that knockdown of GPI in neuronal
cells leads to caspase-dependent apoptotic cell death [91], and
more specifically, to an increased neurotoxicity in primary
cortical neurons via the accumulation of insoluble alpha-
synuclein [38]. Whether such findings relate to GPI
oligomerisation or its receptor is still unclear [92], yet our
identification of Oxr1 as a new regulator of GPI may shed
more light on the complexities of this important moonlighting
protein.
Materials and Methods
Animal Experimentation Constitutive Oxr1 knockout (Oxr1d/
d) mice were derived from the previously described
Oxr1tm1a(EUCOMM)Wtsi line, in which a LacZ reporter was
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inserted in the TLDc domain, while two adjacent exons are
flanked by loxp sites (International Knock-out Mouse
Consortium (IKMC) program, IKMC project 84243) [16,
18]. Oxr1tm1a mice were first crossed with a ubiquitous FlpE
recombinase-expressing line to remove the neomycin selec-
tion cassette in the construct, followed by removal of the FlpE
transgene by backcrossing to C57BL6/J mice. TheseOxr1tm1c
allele-carrying mice were then crossed to a ubiquitous cre-
recombinase expressing line to generate the Oxr1tm1d allele,
followed by removal of the cre transgene by backcrossing to
C57BL6/J and subsequent backcrossing to C57BL6/J for
eight generations. Homozygous Oxr1d/d knockout animals
were generated by intercrossing mice heterozygous for the
Oxr1tm1d allele. Expression of the Oxr1tm1d allele results in
the removal of two exons in the TLDc domain and the intro-
duction of a premature stop codon, removing the terminal 101
amino acids of all Oxr1 protein isoforms (Fig. 1 and
Supplementary Fig. 1). All experiments were conducted in
adherence to the guidelines set forth by the UK Home
Office regulations, and with the approval of the University
of Oxford Ethical Review Panel.
Cell Culture, Transfection, and Treatment Neuronal Neuro2a
(N2a) and HeLa cells were cultures in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with glutamax, 1%
penicillin-streptomycin, and 10% fetal calf serum (all Gibco).
Cells were co-transfected with Fugene 6 (Promega) for 48 h as
per the manufacturer’s protocol. shRNA constructs were from
Sigma (#11857 for Gpi1 and as previously described for Oxr1
[14]). For neurite growth assay, medium was replaced with
serum-free medium when transfecting and incubated for
48 h. For cell death assay, cells were treated with 250-μM
arsenite (Sigma) for 4 h. Cells were fixed with 4% parafor-
maldehyde for 10 min at room temperature, washed with PBS
(Sigma) twice, and blocked with blocking buffer (5% goat
serum (VectorLab), 0.5% Triton X-100 (Sigma)) for 1 h at
room temperature. Neurites and pyknotic nuclei were
visualised with NF200 antibody (Sigma N4142) and DAPI
staining (Vectorlabs), respectively.
Granule Cell Culture and Cell Mobility Assay Cerebella from
P7 pups were dissected in cold HBSS (Gibco), the meninges
removed and were incubated in tryspin (Gibco) for 15 min at
37 °C. The reaction was then stopped by adding trypsin inhib-
itor (Life Technologies) and incubating at room temperature for
5 min. Cerebella were triturated and purified on an Optiprep
gradient [93]. Cells were plated inDMEM (Gibco) supplement-
ed with 0.5-mM glutamine (Gibco). Cell migration was
assessed using an 8.0-μm pore polycarbonate membrane
Transwell inserts (Corning Life Sciences, Acton, MA). The
lower surface of the insert was pre-coated with laminin
(Sigma). Granule cell suspensions (20 × 104 cells) were added
to the upper compartment, and 600-μl culture medium was
added to the lower compartment with recombinant Gpi1
(Abcam ab87625) or vehicle (water). After a 24-h incubation
at 37 °C, the membranes were fixed with 4% paraformaldehyde
for 10 min at room temperature and washed with PBS. Cells on
the upper surface of the membrane were swiped with cotton
swabs and cells that invaded through the membrane to the un-
der membrane were visualised by DAPI staining (VectorLab)
and counted using a fluorescence microscope (Leica).
Immunohistochemistry TUNEL staining on frozen (15 μm)
sections was carried out using the In Situ Cell Death kit as per
the manufacturer’s protocol (Roche). TUNEL-positive cells
from five whole cerebellar sections from the midline of the
brain at 60-μM intervals were counted from each individual
mouse.
Co-Immunoprecipitation, Protein Dimerization, and Western
Blotting To quantify the binding of Gpi1 and Oxr1 in cells,
HeLa cells over-expressing Gpi1 and Oxr1 were washed once
in cold PBS and lysed with cold standard RIPA buffer (50-mM
Tris pH 7.5, 150-mM NaCl, 0.1% SDS, 0.5% sodium
deoxycholate, 1% Triton X-100, all from Sigma) supplement-
ed with protease and phosphatase inhibitor cocktail (Cell
Signaling) by passing the cells through a 23-gauge needle (>
10 strokes). After 30-min incubation on ice and centrifugation
at maximum speed for 20 min at 4 °C, protein content was
quantified by BCA assay (Thermo Scientific). MYC-tagged
proteins were pulled down using 50 μl of anti-MYC EZview
beads (Sigma) and incubated overnight at 4 °C.
Immunoprecipitated proteins were washed three times in
RIPA buffer before being boiled in NuPAGE loading buffer
(Life Technologies) supplemented with β-mercaptoethanol
(Sigma). Proteins were run on pre-cast NuPAGE Bis-Tris gels
(Life Technologies) and transferred as per the manufacturer’s
protocol.
To assess the level of oligomerisation of Gpi1, HeLa cells
were co-transfected with Gpi1 and an empty vector or with
Oxr1-FL or Oxr1-C. After 2-day transfection, cells were
washed once with cold PBS and scraped from the dish surface
i n P B S s u p p l e m e n t e d w i t h e i t h e r 1 - mM
dithiobis(succinimidyl propionate) (DSP, Thermo Scientific)
and lysed by passing through a 23-gauge needle and incu
bated at room temperature for 30 min. The reaction was then
quenched by adding Tris pH 7.8 to reach 50-mM final con-
centration and incubated at room temperature for 15 min. Cell
extracts were clarified by centrifugation at maximum speed at
4 °C for 15 min. For oligomerisation in tissue, mouse cerebel-
la were homogenised in PBS using a tissue Precellys
homogeniser (Bertin Corp.) and centrifuged for 30 min at
4 °C at maximum speed. Protein extract was quantified by
BCA assay (Thermo Scientific). An equal amount of proteins
in Laemmli buffer (Biorad) supplemented with or without β-
mercaptoethanol and boiling as indicated in the figure legends
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was run on 8% SDS-PAGE gels. Primary antibodies used for
western blotting were as follows: Oxr1 (antiserum produced
in the laboratory), HA (Roche 11867423001 and Sigma
H6908), MYC (Sigma M4439), GAPDH (Covance MMS-
580S), Vinculin (Abcam ab73412), Gpi1 (Abcam ab66340),
and α-tubulin (Sigma T5168). Secondary HRP antibodies
were from Invitrogen. Antibody signal was detected using
ECL or ECL prime reagent (GE). The signal was detected
using an ImageQuant LAS4000 (GE Healthcare).
RNA Extraction and Quantitative Real-Time PCR (qRT-PCR)
RNA was extracted from cells or mouse tissue using an
RNeasy mini kit (Qiagen). RNA was reversed transcribed
(RevertAid, Thermo Scientific) and qRT-PCR was performed
in an ABI PRISM 7000 sequence detection system (Applied
Biosystems) using SYBR green PCR master mix (Applied
Biosystems) with primer sequences are shown in Table S2.
The reference gene Gapdh was used as an internal normalis-
ing control. TheΔΔCt method was used to calculate the fold
change as compared to control samples.
Glucose-6-Phosphate Isomerase Glycolytic Activity Gpi1 ac-
tivity was measured in N2a cells transfected for 48 h or in
whole brain or cerebellum using the colorimetric glucose-6-
phosphate isomerase activity assay kit (Abcam), following the
manufacturer’s protocol. Cells and tissue were homogenised
in cold assay buffer supplemented with protease inhibitors
provided. After centrifugation at 12,000 rpm for 10 min at
4 °C, cleared protein samples were measured by BCA assay
(Thermo Scientific) and equal amount of protein was used per
reaction. Immediately after the reaction mix was added to the
samples, absorbance was measured at 450 nm every 5 min for
3 h on a Fluostar Omega plate reader (BMG LabTech). A
standard curve of NADH was generated in parallel using the
NADH provided. After subtracting the background reading to
all values, the Gpi1 activity from the sample was calculated by
applying the difference in absorbance between the two ex-
treme time points of the linear range for the sample to the
NADH standard curve. This value was then corrected by the
reaction time, volume per well, and the dilution factor.
Quantification of Fructose-6-Phosphate (F6P)Mouse cerebella
were homogenised in ice-cold PBS using a Precellys
homogeniser (Bertin Corp.) and extracts were clarified by cen-
trifuged for 10min at maximum speed at 4 °C. Protein amounts
were quantified by BCA assay (Thermo Scientific) and equal
amount of material was then used and deproteinizated using a
deproteinizing sample preparation kit (ab204708). A standard
curve was generated using the F6P provided. Once the reaction
master mix was added to the samples, fluorescence was read on
a Fluostar Omega plate reader (Ex/Em = 544/590) (BMG
LabTech). After subtracting the background reading to all
values, the concentration of F6P in the sample was equals to
the amount of F6P in the sample from the standard curve
corrected for the sample volume added per reaction per well
and the dilution factor.
Glucose Stress Assay To measure glycolysis through proton
production [36], a Seahorse extracellular flux (XF) analyser
(Seahorse Biosciences) was used as per the manufacturer’s
protocol. Briefly, non-purified granule cells were prepared as
described above and were grown in DMEM supplemented
with 0.5-mM L-glutamine and 10% fetal calf serum (Gibco)
on 96-well plates pre-treated with poly-ornithine (Sigma). The
day after splitting, cells were treated with 0.01-mM cytosine-
1-β-D-arabinofuranoside (Sigma) and cultured for 7 days. On
the day of the assay, cells were treated with vehicle or 25-μM
arsenite for 4 h before being transferred to minimum medium
(Seahorse XF glycolysis stress test buffer supplemented with
2-mM L-glutamine Gibco, pH 7.4) for 1 h. To quantify gly-
colysis levels, the glycolysis stress test assay is performed by
first injecting glucose (to feed glycolysis), then oligomycin (to
drive glycolysis), and finally (to inhibit glycolysis).
Glycolysis is determined through measurements of the extra-
cellular acidification rate (ECAR) of the surrounding media in
which glucose, oligomycin, and 2-deoxyglucose (2-DG) are
sequentially added. The ECAR values were normalised to the
protein level per well, as determined by BCA assay at the end
of the run.
Sample Preparation for Metabolomics Profiling Whole cere-
bella were homogenised in 300-μl ice-cold 80%methanol in a
homogeniser vial (Precellys). After centrifugation at maxi-
mum speed for 20 min at 4 °C, protein content was quantified
by BCA assay, and equal amount of sample was filtered
through a 10-kD molecular weight cut-off filters (Amicon)
to remove soluble proteins from the metabolite solution.
Metabolomic Profiling by Ion Chromatography-Tandem Mass
Spectrometry (IC-MS/MS) Each sample was analysed by IC-
MS/MS using an ICS-5000+ ion chromatography system
coupled directly to a Q-Exactive HF Hybrid Quadrupole-
Orbitrap mass spectrometer with a HESI II electrospray
ionisation source (Thermo Scientific) [23–25]. The ion ex-
change chromatography system incorporated an electrolytic an-
ion generator (KOH), which was programmed to produce a
OH− gradient over 37 min. An inline electrolytic suppressor
removed OH− ions and cations from the post-column eluent
stream prior to MS analysis (Thermo Scientific Dionex AERS
500). A 10-μL partial loop injection was used for all analyses,
and the chromatographic separation was performed using a
Thermo Scientific Dionex IonPac AS11-HC 2 × 250 mm,
4-μm particle size column with a Dionex Ionpac AG11-HC
4-μm 2 × 50 guard column inline. The IC flow rate was
0.250 mL/min. The total run time was 37 min and the hydrox-
ide ion gradient comprised as follows: 0 min, 0 mM; 1 min,
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0 mM; 15 min, 60 mM; 25 min, 100 mM; 30 min, 100 mM;
30.1 min, 0 mM; and 37 min, 0 mM. Analysis was performed
in negative ion mode using a scan-range from m/z 60–900 and
resolution set to 70,000. The tune file source parameters were
set as follows: sheath gas flow 60 mL/min; Aux gas flow
20 mL/min; spray voltage 3.6v; capillary temperature 320 °C;
S-lens RF value 70; heater temperature 350 °C. AGC target was
set to 1e6v ions and the Max IT value was 250 ms. The column
temperature was kept at 30 °C throughout the experiment. Full
scan data were acquired in continuum mode.
Processing and Data Analysis Raw data files were processed
using ProgenesisQI (Waters) [23–25]. This process included
alignment of retention times, peak picking by identification of
the presence of natural abundance isotope peaks, characterising
multiple adducts forms and identification of metabolites using
an in house database. Retention times, accurate mass values,
relative isotope abundances, and fragmentation patterns were
compared between authentic standards and the samples mea-
sured. Identifications were accepted only when the following
criteria were met: < 5-ppm differences between measured and
theoretical mass (based on chemical formula), < 30-s differ-
ences between authentic standard and analyte retention times,
and isotope peak abundance measurements for analytes were >
90%matched to the theoretical value generated from the chem-
ical formula. Where measured, fragmentation patterns were
matched to the base peak and two additional peak matches in
the MS/MS spectrum to within 12 ppm. The top 10 data direct-
ed fragmentation method was not always able to provide frag-
ment ions for all ions measured in theMS 1 spectrum. PCAwas
performed using the capability for this output in Progenesis QI
and SIMCA 14 (Umetrics). This analysis is Bun-supervised^
and retains no Bknowledge^ of the experimental groups them-
selves; so, this approach is useful for confirming compound
abundance similarities and differences between groups of sam-
ples and for identifying any sample outliers. Fold change, %
coefficient of variation (%CV) and p values were generated
automatically in Progenesis QI and verified manually using a
normalised abundance output and Excel. Heat maps were gen-
erated manually using the verified fold-change output.
ModellingAmodel of the mouse TLDc domainwas generated
with Modeler [94] using the structure of the zebrafish TLDc
(PDB: 4ACJ) as a template [73]. The sequence alignment
between the two proteins was performed with Clustal
Omega [95] achieving a 62% sequence identity. The resulting
structure was subsequently used to predict its interface with
Gpi1 (PDB: 1U0E) using the Cluspro server [53, 96]. An
exhaustive rigid-body protein docking was performed using
Cluspro followed by a clustering of the results, which are also
energy minimised. As the size of each cluster is proportional
to its probability of being the lowest energy configuration
[96], the most populated cluster is the most likely to represent
the most favourable interaction interface between two pro-
teins. The same interface was reproduced using the three scor-
ing schemes implemented in Cluspro (i.e. balanced, electro-
static-favoured, and hydrophobic-favoured) as well as the
Bothers mode,^ which is designed to fit protein interactions
differing from the enzyme-inhibitor and multi-subunit pro-
teins used to parameterize the scoring schemes above. In all
cases, the most populated cluster was at least 2 to 4 times
larger than the secondmost populated, as indicated to increase
the level of certainty 5.
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